[Adverse events associated with temsirolimus for patients with metastatic renal cell carcinoma]

Area of Science:

• Oncology
• Pharmacology

Background:

• Temsirolimus is a mammalian target of rapamycin inhibitor with demonstrated efficacy in advanced renal cell carcinoma (RCC).
• Previous trials show significant adverse events (AEs), including asthenia, anemia, and hyperglycemia, with a notable incidence of drug-related pneumonitis.

Purpose of the Study:

• To analyze the safety profile of temsirolimus in a large cohort of Japanese RCC patients.
• To characterize temsirolimus-related adverse events (AEs) in this specific population.
• To discuss the clinical significance of managing AEs during temsirolimus treatment.

Main Methods:

• Retrospective analysis of clinical data from Japanese patients treated with temsirolimus.
• Focus on the incidence, severity, and types of adverse events (AEs).
• Comparison of AE profiles with data from Western populations.

Main Results:

• The frequency and severity of temsirolimus-related adverse events (AEs) in Japanese patients are comparable to those observed in Western populations.
• Common AEs include asthenia, anemia, and hyperglycemia.
• Temsirolimus-related pneumonitis was observed, necessitating careful monitoring.

Conclusions:

• Temsirolimus is a viable treatment option for advanced RCC in Japanese patients.
• AEs associated with temsirolimus in Japanese patients mirror those in Western cohorts.
• Proactive management of adverse events is crucial for optimizing temsirolimus therapy in RCC.